Allogene Therapeutics, Inc.
For the period ended Nov 5, 2026. Filed Nov 5, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Nov 5, 2026 · Filed Nov 5, 2026
Use the contents to explore the available documents and sections.
ALLO$1.04-4.6%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · SELECTED FINANCIAL DATA
SELECTED FINANCIAL DATA
(unaudited; in thousands, except share and per share data)
STATEMENTS OF OPERATIONS
| Three Months Ended September 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Collaboration revenue - related party | $— | $— |
| Operating expenses: | ||
| Research and development | $41,934 | $31,164 |
| General and administrative | 12,859 | 13,737 |
| Total operating expenses | 54,793 | 44,901 |
| Loss from operations | (54,793) | (44,901) |
| Other income (expenses), net: | ||
| Interest and other income, net | 4,879 | 3,926 |
| Interest expense | (379) | (344) |
| Other income (expenses), net | (76) | (81) |
| Total other income (expenses), net | 4,424 | 3,501 |
| Net loss | $(50,369) | $(41,400) |
| Net loss per share, basic and diluted | $(0.15) | $(0.19) |
| Weighted-average number of shares used in computing net loss per share, basic and diluted | 346,092,814 | 222,038,680 |
SELECTED BALANCE SHEET DATA
| As of September 30, 2026 | As of December 31, 2025 | |
|---|---|---|
| Cash, cash equivalents and investments | $388,873 | $258,253 |
| Total assets | 511,320 | 415,905 |
| Total liabilities | 118,768 | 123,363 |
| Total stockholders’ equity | 392,552 | 292,542 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.